NITROFURANTOIN (Furadantin) has become increasingly useful in the treatment of resistant urinary-tract infections and is now widely employed. Nitrofurazone (Furacin), which is used topically in chr ...

Tyche Industries Share Price Today 16 May 2025: Track Tyche Industries share price today on NSE/BSE with real-time updates. Check stock performance, fundamentals, market cap, shareholding ...

The urinary recovery of nitrofurantoin after a single 100-mg oral dose was studied in subjects with varying renal function. Almost all uremic patients excreted little or no drug in the urine during ...

Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving treatment options for millions of women.

Currently, the most common treatment for uncomplicated UTIs in women is nitrofurantoin, an antibiotic that has been in use since the 1950s. Other options include trimethoprim-sulfamethoxazole and ...

The FDA has approved Blujepa (gepotidacin) for the treatment of female patients 12 years of age and older weighing at least 40kg with uncomplicated UTI.

The FDA has approved Blujepa, a groundbreaking new antibiotic for treating uncomplicated urinary tract infections in women, marking the first new class of UTI medication in nearly three decades.

Blujepa marks the first new oral antibiotic to gain FDA approval for uncomplicated urinary tract infections in nearly 30 years.

The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract infections (UTIs) in nearly 30 years.

Despite major changes in the prevalence of antibiotic resistance, the 2011 IDSA guideline for uncomplicated UTI still accurately reflects the efficacy and safety of first-line treatments.